Bruno Anglaret

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Thierry Façon, Jean Yves Mary, Cyrille Hulin et al. · The Lancet · 2007 · 870 citations

Hematological Malignancy, Cell Therapy, Transplantation +14

Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma

Thierry Façon, J. Jenifer Florence Mary, Jean‐Luc Harousseau et al. · Journal of Clinical Oncology · 2006 · 195 citations

Elderly Patients, Immunology, Pharmacotherapy +18

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry

Pauline Brice, Réda Bouabdallah, Philippe Moreau et al. · Bone Marrow Transplantation · 1997 · 161 citations

Prognostic Factors, Cell Therapy, French Registry +10

Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.

Jean‐Yves Blay, Franck Chauvin, Axel Le Cesne et al. · Journal of Clinical Oncology · 1996 · 157 citations

Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience

Hervé Avet‐Loiseau, Cyrille Hulin, L. Campion et al. · Journal of Clinical Oncology · 2013 · 114 citations · Full text